Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Julian A Barden
Biosceptre (Aust) Pty Ltd, Riverside Life Sciences,
11 Julius Ave, North Ryde, N.S.W. 2113
Australia
Research Article
Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X7
Author(s): Julian A Barden, Angus Gidley-Baird, Liew Cheng Teh, G-Halli Rajasekariah, John Pedersen, Neil I Christensen, Derek Spielman and David M AshleyJulian A Barden, Angus Gidley-Baird, Liew Cheng Teh, G-Halli Rajasekariah, John Pedersen, Neil I Christensen, Derek Spielman and David M Ashley
The degree of unmet need for new therapeutics in oncology is clear since about 30% of the population die from cancer with enormous associated costs in health care and in personal impact. New and preferably specific targets are needed now to address the problem, both to improve overall survival and importantly to reduce side effects in order to improve quality of life. nfP2X7 is a receptor that, unlike P2X7, cannot enable apoptosis in cancer cells. Having established the widespread coverage of human cancers in which the aberrant receptor is found, attention has been drawn to the therapeutic potential of the target and whether an immunotherapeutic approach is capable of providing a significant therapeutic response. We demonstrate the intrinsic target specificity, the delivery of antibody within target cells, the extremely good safety profile of the targeting antibody and the broad range.. View More»
DOI:
10.4172/2155-9899.1000432